切换至 "中华医学电子期刊资源库"

中华脑血管病杂志(电子版) ›› 2026, Vol. 20 ›› Issue (04) : 396 -402. doi: 10.3877/cma.j.issn.1673-9248.2026.04.007

临床研究

应激性血糖升高比值预测急性缺血性脑卒中静脉溶栓预后的价值
胡琼丹1, 侯善兵2, 陈霞3,(), 王教媛4, 戴晓熹3   
  1. 1 230001 安徽合肥,中国科学技术大学附属第一医院南区护理部
    2 230001 安徽合肥,中国科学技术大学附属第一医院南区急诊科
    3 230001 安徽合肥,中国科学技术大学附属第一医院护理部
    4 230001 安徽合肥,中国科学技术大学附属第一医院门诊部
  • 收稿日期:2026-04-30 出版日期:2026-08-01
  • 通信作者: 陈霞
  • 基金资助:
    中华护理学会科研课题(ZHKY202416)

Predictive value of stress hyperglycemia ratio for prognosis in acute ischemic stroke patients treated with intravenous thrombolysis

Qiongdan Hu1, Shanbing Hou2, Xia Chen3,(), Jiaoyuan Wang4, Xiaoxi Dai3   

  1. 1 Department of Nursing, South Campus, the First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China
    2 Department of Emergency, South Campus, the First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China
    3 Department of Nursing, the First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China
    4 Department of Outpatient, the First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China
  • Received:2026-04-30 Published:2026-08-01
  • Corresponding author: Xia Chen
引用本文:

胡琼丹, 侯善兵, 陈霞, 王教媛, 戴晓熹. 应激性血糖升高比值预测急性缺血性脑卒中静脉溶栓预后的价值[J/OL]. 中华脑血管病杂志(电子版), 2026, 20(04): 396-402.

Qiongdan Hu, Shanbing Hou, Xia Chen, Jiaoyuan Wang, Xiaoxi Dai. Predictive value of stress hyperglycemia ratio for prognosis in acute ischemic stroke patients treated with intravenous thrombolysis[J/OL]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2026, 20(04): 396-402.

目的

分析应激性血糖升高比值(SHR)与急性缺血性脑卒中(AIS)患者静脉溶栓预后的关系。

方法

回顾性收集2022年1月至2023年12月就诊于中国科学技术大学附属第一医院并进行静脉溶栓治疗的158例AIS患者为研究对象,通过院内电子病历系统收集患者基线临床资料。根据患者发病后90 d神经功能恢复情况[改良Rankin量表(mRS)评分]将其分为预后良好组(mRS评分≤3分)和预后不良组(mRS评分>3分)。采用单因素分析(t检验、秩和检验或χ2检验)比较2组患者溶栓前一般临床资料和实验室检查指标等的差异。采用单因素Logistic回归分析筛选影响静脉溶栓预后的因素,并利用多因素Logistic回归模型(控制不同的混杂因素)分析SHR与静脉溶栓预后的相关性;利用限制性立方样条模型进一步分析SHR与静脉溶栓预后的非线性关联。

结果

在158例AIS患者中,预后良好组患者135例(85.44%),预后不良组患者23例(14.56%)。相较于预后不良组患者,预后良好组患者的外周血白蛋白、尿酸、低密度脂蛋白胆固醇(LDL-C)、总胆固醇、谷草转氨酶水平更高[(44.20±4.66)g/L vs(40.24±5.43)g/L;(348.89±95.39)μmol/L vs(305.54±86.36)μmol/L;(2.76±0.89)mmol/L vs(2.35±0.56)mmol/L;(4.69±1.12)mmol/L vs(4.00±0.70)mmol/L;22.00(18.00,28.30)U/L vs 19.00(15.00,24.80)U/L],差异均有统计学意义(t=3.672,P<0.001;t=2.041,P=0.043;t=2.091,P=0.038;t=2.780,P=0.006;Z=-2.096,P=0.036);预后良好组患者的溶栓前美国国立卫生研究院卒中量表(NIHSS)评分、直接胆红素(DBIL)和SHR均显著低于预后不良组患者[6.00(3.00,11.00)分 vs 16.00(11.00,20.00)分;3.20(2.10,4.60)μmol/L vs 4.20(2.90,5.60)μmol/L;1.02(0.89,1.18)vs 1.19(1.02,1.46)],差异均有统计学意义(Z=-4.915,P<0.001;Z=-2.695,P=0.007;Z=-2.576,P=0.010)。单因素Logistic回归分析结果显示:SHR(OR=5.184, 95%CI: 1.202~22.360)、溶栓前NIHSS评分(OR=1.189, 95%CI: 1.101~1.283)、白蛋白(OR=0.830, 95%CI: 0.749~0.920)、尿酸(OR=0.994, 95%CI: 0.989~1.000)、LDL-C(OR=0.515, 95%CI: 0.273~0.971)、总胆固醇(OR=0.467, 95%CI: 0.266~0.820)和DBIL(OR=1.483, 95%CI: 1.154~1.906)均是影响AIS患者静脉溶栓预后的危险因素(P均<0.05)。多因素Logistic回归分析结果显示:在调整不同混杂因素后,SHR仍是影响AIS患者静脉溶栓预后的独立危险因素,且SHR与AIS患者静脉溶栓预后呈显著正相关。限制性立方样条模型结果显示:SHR与AIS患者静脉溶栓预后存在非线性关联。当SHR<1.03时,AIS患者预后不良风险随SHR升高而缓慢上升;当SHR≥1.03时,AIS患者预后不良风险随SHR升高而快速上升。

结论

对于接受静脉溶栓治疗的AIS患者,较高的SHR与发病后90 d预后不良相关。

Objective

To analyze the relationship between the stress hyperglycemia ratio (SHR) and the prognosis of acute ischemic stroke (AIS) patients treated with intravenous thrombolysis (IVT).

Methods

This retrospective study included 158 AIS patients who underwent IVT at the First Affiliated Hospital of the University of Science and Technology of China between January 2022 and December 2023. Baseline clinical data were collected via the hospital's electronic medical record system. Patients were divided into a favorable- [modified Rankin scale (mRS) score ≤3] and a poor-prognosis (mRS score >3) groups based on neurological recovery at 90 days. Univariate analysis (t-test, Mann-Whitney U test, or χ2 test) compared general clinical data and laboratory indicators between the two groups. Univariate Logistic regression identified factors associated with poor prognosis, while multivariate Logistic regression (adjusted for confounders) analyzed the independent association between SHR and IVT outcomes. Restricted cubic spline models further assessed nonlinear associations between SHR and prognosis.

Results

Among 158 AIS patients, 135 (85.4%) had favorable IVT outcomes and 23 (14.6%) had poor outcomes. Compared with the poor-prognosis group, the favorable-prognosis group showed significantly higher levels of albumin [(44.20±4.66) g/L vs (40.24±5.43) g/L, t=3.672, P<0.001], uric acid [(348.89±95.39) μmol/L vs (305.54±86.36) μmol/L, t=2.041, P=0.043], LDL-C [(2.76±0.89) mmol/L vs (2.35±0.56) mmol/L, t=2.091, P=0.038], total cholesterol [(4.69±1.12) mmol/L vs (4.00±0.70) mmol/L, t=2.780, P=0.006], and aspartate aminotransferase [22.00 (18.00, 28.30) U/L vs 19.00 (15.00, 24.80) U/L, Z=-2.096, P=0.036]. Conversely, the favorable-prognosis group had significantly lower NIHSS scores before thrombolysis [6.00 (3.00, 11.00) vs 16.00 (11.00, 20.00), Z=-4.915, P<0.001], direct bilirubin [3.20 (2.10, 4.60) μmol/L vs 4.20 (2.90, 5.60) μmol/L, Z=-2.695, P=0.007], and SHR [1.02 (0.89, 1.18) vs 1.19 (1.02, 1.46), Z=-2.576, P=0.010]. Univariate Logistic regression identified SHR (OR=5.184, 95%CI: 1.202 - 22.360), NIHSS score before thrombolysis (OR=1.189, 95%CI: 1.101 - 1.283), albumin (OR=0.830, 95%CI: 0.749 - 0.920), uric acid (OR=0.994, 95%CI: 0.989 - 1.000), LDL-C (OR=0.515, 95%CI: 0.273 - 0.971), total cholesterol (OR=0.467, 95%CI: 0.266 - 0.820), and direct bilirubin (OR=1.483, 95%CI: 1.154 - 1.906) as factors associated with poor prognosis (all P<0.05). Multivariate analysis confirmed SHR as an independent predictor of poor IVT outcomes after adjusting for confounders. Restricted cubic spline models revealed a nonlinear relationship: when SHR was <1.03, the risk of poor prognosis increased slowly with rising SHR; when SHR was ≥1.03, the risk escalated rapidly.

Conclusion

In AIS patients receiving IVT, elevated SHR is independently associated with poor 90-day outcomes.

表1 急性缺血性脑卒中静脉溶栓不同预后组患者基线临床资料比较
项目 预后良好组(n=135) 预后不良组(n=23) 统计值 P
性别[例(%)] χ2=1.699 0.250
男性 84(62.22) 11(47.83)
女性 51(37.78) 12(52.17)
年龄(岁,
±s
65.62±12.66 66.96±16.78 t=-0.444 0.657
吸烟史[例(%)] χ2=0.173 0.807
41(30.37) 6(26.09)
94(69.63) 17(73.91)
饮酒史[例(%)] χ2=0.042 0.523
44(32.59) 7(30.43)
91(67.41) 16(69.57)
溶栓前NIHSS评分[分,MQ1Q3)] 6.00(3.00,11.00) 16.00(11.00,20.00) Z=-4.915 <0.001
白细胞计数(×109/L,
±s
7.98±2.76 7.90±2.68 t=0.128 0.898
白蛋白(g/L,
±s
44.20±4.66 40.24±5.43 t=3.672 <0.001
尿酸(μmol/L,
±s
348.89±95.39 305.54±86.36 t=2.041 0.043
HDL-C(mmol/L,
±s
1.04±0.32 1.06±0.21 t=-0.261 0.795
LDL-C(mmol/L,
±s
2.76±0.89 2.35±0.56 t=2.091 0.038
总胆固醇(mmol/L,
±s
4.69±1.12 4.00±0.70 t=2.780 0.006
中性粒细胞计数[×109/L,MQ1Q3)] 4.66(3.69,6.09) 5.68(3.80,7.42) Z=-1.003 0.316
淋巴细胞计数[×109/L,MQ1Q3)] 1.83(1.30,2.55) 1.49(0.80,2.30) Z=-1.521 0.128
单核细胞计数[×109/L,MQ1Q3)] 0.41(0.31,0.53) 0.36(0.32,0.46) Z=-1.642 0.100
红细胞计数[×1012/L,MQ1Q3)] 140.00(128.00,150.00) 135.50(117.00,152.00) Z=-1.287 0.198
血小板计数[×109/L,MQ1Q3)] 181.50(156.00,224.00) 179.50(167.00,218.00) Z=-0.690 0.490
ALT[U/L,MQ1Q3)] 18.00(14.00,26.00) 16.50(13.00,21.00) Z=-1.599 0.110
AST[U/L,MQ1Q3)] 22.00(18.00,28.30) 19.00(15.00,24.80) Z=-2.096 0.036
DBIL[μmol/L,MQ1Q3)] 3.20(2.10,4.60) 4.20(2.90,5.60) Z=-2.695 0.007
血肌酐[μmol/L,MQ1Q3)] 69.50(57.00,86.80) 69.00(60.00,80.00) Z=-0.227 0.821
尿素氮[mmol/L,MQ1Q3)] 6.15(5.00,7.40) 5.70(4.40,7.20) Z=-1.423 0.155
血糖[mmol/L,MQ1Q3)] 7.32(6.22,9.86) 7.25(6.30,13.64) Z=-0.560 0.575
甘油三酯[mmol/L,MQ1Q3)] 1.56(1.13,2.36) 1.40(0.74,1.83) Z=-1.681 0.093
SHR[MQ1Q3)] 1.02(0.89,1.18) 1.19(1.02,1.46) Z=-2.576 0.010
表2 急性缺血性脑卒中患者静脉溶栓预后危险因素的单因素Logistic回归分析结果
表3 SHR与急性缺血性脑卒中患者溶栓效果关系的多因素Logistic回归分析结果
图1 应激性血糖升高比值(SHR)与急性缺血性脑卒中患者静脉溶栓预后效果关系的限制性立方样条曲线
1
《中国脑卒中防治报告》编写组. 《中国脑卒中防治报告2020》概要[J]. 中国脑血管病杂志, 2022, 19(2): 136-144.
2
GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Neurol, 2021, 20(10): 795-820.
3
World Health Organization. Global health estimates 2020: deaths by cause, age, sex, by country and by region, 2000-2019[EB/OL]. (2022-03-08) [2025-10-28].
4
Li Z, Jiang Y, Li H, et al. China's response to the rising stroke burden[J]. BMJ, 2019, 364: l879.
5
中国卒中学会, 中国卒中学会神经介入分会, 中华预防医学会卒中预防与控制专业委员会介入学组. 急性缺血性卒中血管内治疗中国指南2023[J]. 中国卒中杂志, 2023, 18(6): 684-711.
6
罗云, 李政, 张佳慧, 等. 脑干梗死与急性应激性血糖升高率的相关性[J]. 中国医师进修杂志, 2019, 42(8): 678-681.
7
Allport LE, Butcher KS, Baird TA, et al. Insular cortical ischemia is independently associated with acute stress hyperglycemia[J]. Stroke, 2004, 35(8): 1886-1891.
8
Roberts GW, Quinn SJ, Valentine N, et al. Relative hyperglycemia, a marker of critical illness: introducing the stress hyperglycemia ratio[J]. J Clin Endocrinol Metab, 2015, 100(12): 4490-4497.
9
Tziomalos K, Dimitriou P, Bouziana SD, et al. Stress hyperglycemia and acute ischemic stroke in-hospital outcome[J]. Metabolism, 2017, 67: 99-105.
10
李涛, 管仁苹, 何阳, 等. 应激性血糖升高比值与重症急性肾损伤患者院内死亡风险的关系[J]. 中国急救医学, 2023, 43(5): 356-360.
11
Yang Y, Kim TH, Yoon KH, et al. The stress hyperglycemia ratio, an index of relative hyperglycemia, as a predictor of clinical outcomes after percutaneous coronary intervention[J]. Int J Cardiol, 2017, 241: 57-63.
12
Lee TF, Drake SM, Roberts GW, et al. Relative hyperglycemia is an independent determinant of in-hospital mortality in patients with critical illness[J]. Crit Care Med, 2020, 48(2): e115-e122.
13
Baker EH, Janaway CH, Philips BJ, et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease[J]. Thorax, 2006, 61(4): 284-289.
14
Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview[J]. Lancet, 2000, 355(9206): 773-778.
15
刘欣, 聂曦明, 濮月华, 等. 应激性高血糖指数与急性缺血性卒中血管内治疗患者预后的关联[J]. 中华医学杂志, 2022, 102(27): 2096-2102.
16
中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9): 666-682.
17
Xu AD, Wang YJ, Wang DZ, et al. Consensus statement on the use of intravenous recombinant tissue plasminogen activator to treat acute ischemic stroke by the Chinese Stroke Therapy Expert Panel[J]. CNS Neurosci Ther, 2013, 19(8): 543-548.
18
Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2013, 44(3): 870-947.
19
Levy EI, Siddiqui AH, Crumlish A, et al. First Food and Drug Administration-approved prospective trial of primary intracranial stenting for acute stroke: SARIS (stent-assisted recanalization in acute ischemic stroke)[J]. Stroke, 2009, 40(11): 3552-3556.
20
Su YW, Hsu CY, Guo YW, et al. Usefulness of the plasma glucose concentration-to-HbA1c ratio in predicting clinical outcomes during acute illness with extreme hyperglycaemia[J]. Diabetes Metab, 2017, 43(1): 40-47.
21
Huang B, Qian F, Fan X, et al. Efficacy and safety of intravenous thrombolysis with alteplase for treating acute ischemic stroke at different time windows: a protocol for systematic review and Meta-analysis[J]. Medicine (Baltimore), 2020, 99(52): e23620.
22
Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a Meta-analysis of individual patient data from randomised trials[J]. Lancet, 2014, 384(9958): 1929-1935.
23
Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2018, 49(3): e46-e110.
24
Wang Z, Li J, Wang C, et al. Gender differences in 1-year clinical characteristics and outcomes after stroke: results from the China National Stroke Registry[J]. PLoS One, 2013, 8(2): e56459.
25
Ingels C, Gunst J, van den Berghe G. Endocrine and metabolic alterations in sepsis and implications for treatment[J]. Crit Care Clin, 2018, 34(1): 81-96.
26
Chu J, Tang J, Lai Y, et al. Association of stress hyperglycemia ratio with intracoronary thrombus burden in diabetic patients with ST-segment elevation myocardial infarction[J]. J Thorac Dis, 2020, 12(11): 6598-6608.
27
李露茜, 张新欣, 梁璐, 等. 应激性血糖升高比值对急性呼吸衰竭患者短期预后的预测价值[J]. 浙江医学, 2023, 45(7): 748-750.
28
Rosenberg GA. Matrix metalloproteinases in neuroinflammation[J]. Glia, 2002, 39(3): 279-291.
29
Schmidt AM. Highlighting diabetes mellitus: the epidemic continues[J]. Arterioscler Thromb Vasc Biol, 2018, 38(1): e1-e8.
30
Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia[J]. Lancet, 2009, 373(9677): 1798-1807.
31
Chen G, Ren J, Huang H, et al. Admission random blood glucose, fasting blood glucose, stress hyperglycemia ratio, and functional outcomes in patients with acute ischemic stroke treated with intravenous thrombolysis[J]. Front Aging Neurosci, 2022, 14: 782282.
32
Baird TA, Parsons MW, Phan T, et al. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome[J]. Stroke, 2003, 34(9): 2208-2214.
33
Bar-Or D, Rael LT, Madayag RM, et al. Stress hyperglycemia in critically ill patients: insight into possible molecular pathways[J]. Front Med (Lausanne), 2019, 6: 54.
34
Guo Y, Wang G, Jing J, et al. Stress hyperglycemia may have higher risk of stroke recurrence than previously diagnosed diabetes mellitus[J]. Aging (Albany NY), 2021, 13(6): 9108-9118.
35
Pan Y, Cai X, Jing J, et al. Stress hyperglycemia and prognosis of minor ischemic stroke and transient ischemic attack: the CHANCE study (clopidogrel in high-risk patients with acute nondisabling cerebrovascular events)[J]. Stroke, 2017, 48(11): 3006-3011.
36
吴伏鹏, 朱晓光, 李梅芳, 等. 应激性血糖升高比值对急性心力衰竭患者预后的评估价值[J]. 中华急诊医学杂志, 2021, 30(3): 318-322.
37
Li J, Quan K, Wang Y, et al. Effect of stress hyperglycemia on neurological deficit and mortality in the acute ischemic stroke people with and without diabetes[J]. Front Neurol, 2020, 11: 576895.
38
Zhu B, Pan Y, Jing J, et al. Stress hyperglycemia and outcome of non-diabetic patients after acute ischemic stroke[J]. Front Neurol, 2019, 10: 1003.
39
El Gendy HA, Mohamed MA, Abd Elhamid AE, et al. Stress hyperglycemia as a prognostic factor in acute ischemic stroke patients: a prospective observational cohort study[J]. Ain-Shams J Anesthes, 2021, 13: 4.
40
Ngiam JN, Cheong CWS, Leow AST, et al. Stress hyperglycaemia is associated with poor functional outcomes in patients with acute ischaemic stroke after intravenous thrombolysis[J]. QJM, 2022, 115(1): 7-11.
41
Suissa L, Panicucci E, Perot C, et al. Effect of hyperglycemia on stroke outcome is not homogeneous to all patients treated with mechanical thrombectomy[J]. Clin Neurol Neurosurg, 2020, 194: 105750.
42
Rosso C, Pires C, Corvol JC, et al. Hyperglycaemia, insulin therapy and critical penumbral regions for prognosis in acute stroke: further insights from the INSULINFARCT trial[J]. PLoS One, 2015, 10(3): e0120230.
43
Shao B, Bayraktutan U. Hyperglycaemia promotes cerebral barrier dysfunction through activation of protein kinase C-β[J]. Diabetes Obes Metab, 2013, 15(11): 993-999.
[1] 江伟东, 陈博. 早发性可切除胃癌的临床病理特征及预后列线图模型的建立[J/OL]. 中华普通外科学文献(电子版), 2026, 20(04): 230-237.
[2] 张彬, 王敏, 郑鹏, 冯犁, 李鑫, 赵高平. 早期胃癌淋巴结转移的危险因素及预后分析[J/OL]. 中华普外科手术学杂志(电子版), 2026, 20(04): 337-342.
[3] 李若隐, 罗义, 张雪琳, 雷李凤, 李思丽. MDSCs相关基因在乳腺癌中表达特征分析与风险预测模型构建[J/OL]. 中华普外科手术学杂志(电子版), 2026, 20(04): 366-373.
[4] 张鹏, 舒芳, 肖赟, 吴书清, 钟斌. 针式抓钳辅助单孔腹腔镜在治疗小儿腹股沟嵌顿斜疝中的应用[J/OL]. 中华疝和腹壁外科杂志(电子版), 2026, 20(03): 334-340.
[5] 李春艳, 郎广碧, 周亚, 陈晓龙, 胡明冬. 胸部SMARCA4缺失型非小细胞肺癌与SMARCA4缺失型未分化肿瘤的组织病理学特征、影像学表现及预后分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 534-541.
[6] 王倩, 韩星, 朱宁, 陈雷, 张耐. 肺动脉造影测定肺动脉扩张性在急性肺栓塞患者风险分层中的应用研究[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 593-599.
[7] 陈玥, 吴丙琳, 冯妮娜, 杨勤秦, 苗雄伟, 尚苗苗, 马静, 王欢, 任巧微. 中性粒细胞/淋巴细胞比值预测免疫治疗联合化疗晚期NSCLC患者预后的临床意义[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 607-614.
[8] 张群, 邱炳峰, 陶鸿杰. 血清肿瘤标志物及支气管肺泡灌洗液炎症细胞预测社区获得性肺炎患者预后的临床意义[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 676-679.
[9] 齐洪武, 徐泽雨. 脑脓肿的临床诊治进展[J/OL]. 中华临床医师杂志(电子版), 2026, 20(04): 327-331.
[10] 张爽, 谢琦, 杨清武. 急性缺血性脑卒中无效再通的研究进展及脑保护新策略[J/OL]. 中华脑血管病杂志(电子版), 2026, 20(04): 351-358.
[11] 戴荣源, 裴月红, 孙庆利, 黄骁, 张淦, 樊东升, 傅瑜. 美国心脏协会/美国卒中协会《2026年急性缺血性脑卒中患者早期管理指南》更新概述[J/OL]. 中华脑血管病杂志(电子版), 2026, 20(04): 359-364.
[12] 严志忠, 张旭, 陈军辉, 操加明, 赵麒文, 沈浏艳, 时忠华, 杨清武, 王玉海. 胆固醇-高密度脂蛋白胆固醇-葡萄糖指数对急性基底动脉闭塞行血管内治疗后临床结局的预测价值[J/OL]. 中华脑血管病杂志(电子版), 2026, 20(04): 365-371.
[13] 曾陈颖, 陈云清, 徐祖兵, 余求龙, 林晶, 洪道俊, 涂琪. 炎症标志物在大梗死核心与非大梗死核心急性缺血性脑卒中行血管内治疗的预后价值[J/OL]. 中华脑血管病杂志(电子版), 2026, 20(04): 372-379.
[14] 魏宸铭, 牟婧宇, 赵心怡, 陈乐, 武剑. 不同评分量表对前循环大血管闭塞性脑卒中诊断预测性能的差异[J/OL]. 中华脑血管病杂志(电子版), 2026, 20(04): 380-388.
[15] 康志霞, 班玉霞, 白如玉, 郝美美, 李正正, 苏琴琴. 血浆致动脉硬化指数和程序性细胞死亡因子4预测急性缺血性脑卒中神经功能缺损及预后的价值[J/OL]. 中华脑血管病杂志(电子版), 2026, 20(04): 389-395.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?